Feb 18, 2021
MindMed Reaches Agreement to Acquire HealthMode, a Leading Machine Learning Digital Medicine Company
Feb 17, 2021
MindMed's LSD Neutralizer Study Begins
Feb 11, 2021
MindMed Signs Partnership with Swiss Psychedelic Drug Discovery Startup MindShift Compounds AG, Expands Development Pipeline and IP Portfolio with Next-Gen Psychedelic and Empathogenic Compounds
Jan 20, 2021
MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA and LSD
Jan 14, 2021
MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience
Nov 24, 2020
MindMed to Launch Albert, A Digital Medicine Division for Psychedelic Medicines
Nov 16, 2020
MindMed Receives Approval of Protocol Design to Evaluate Microdoses of LSD For Adult ADHD In Phase 2a Clinical Trial from Swiss and Dutch Health Authorities
Nov 13, 2020
MindMed Announces Q3 2020 Financial Results;
Sep 24, 2020
MindMed and Liechti Lab Announce R&D Collaboration On Psilocybin
Sep 23, 2020
MindMed Confirms No Material Change
Sep 21, 2020
MindMed Submits Application For NASDAQ Up-Listing, Appoints Canaccord Genuity As Financial Advisor
Aug 25, 2020
MindMed Announces First-Ever Clinical Trial Combining MDMA and LSD
Aug 14, 2020
Mind Medicine (MindMed) Inc. Announces Q2 2020 Financial Results
Aug 13, 2020
MindMed Expanding R&D in Europe, Appoints Dr. Miri Halperin Wernli As President
Aug 06, 2020
MindMed Adds Psychedelic Assisted Therapy Expert Dr. Peter Gasser As Clinical Advisor For Project Lucy
Jul 28, 2020
MindMed Completes Dosing 18-MC Phase 1 Study
Jun 26, 2020
MindMed Building Diverse Pipeline and Leadership Position in Psychedelic Inspired Medicines Industry
Jun 24, 2020
MindMed Developing IP For Personalized Psychedelic Assisted Therapies
Jun 18, 2020
MindMed To Evaluate Ayahuasca's Active Ingredient DMT In Phase 1 Clinical Trial Collaboration
Jun 08, 2020
Phase 2 Clinical Trial of LSD for "Suicide Headaches" Begins Treating Patients